SciTech's ST-001 nanoFenretinide Shows Early Clinical Benefit in Cutaneous T-Cell Lymphoma Phase 1a Trial
核心洞察
SciTech Development's Phase 1a trial of ST-001 nanoFenretinide (搜索) demonstrates meaningful anti-tumor activity with complete and partial responses in previously treated cutaneous T-cell lymphoma (搜索) patients.
The proprietary nanoparticle delivery platform achieves enhanced systemic exposure, addressing longstanding bioavailability limitations of fenretinide while maintaining manageable toxicity.
The fully enrolled Phase 1a trial is nearing completion with data supporting advancement to the next phase of clinical development.
SciTech Development Inc. (搜索) announced that early-stage clinical data from its ongoing Phase 1a trial of ST-001 nanoFenretinide (搜索) will be presented at the USCLC Annual Workshop 2026 in Denver, Colorado. The presentation will highlight emerging data demonstrating meaningful anti-tumor activity in patients with Cutaneous T-Cell Lymphoma (搜索) (CTCL), a subtype of T-cell non-Hodgkin lymphoma (搜索).
Clinical Efficacy and Safety Profile
Principal investigator Auris Huen, MD, PharmD, associate professor of Dermatology at The University of Texas MD Anderson Cancer Center, will present findings titled "Clinical Benefit, High Systemic Exposure, and Manageable Toxicity in a First-in-Human Trial of ST-001 nanoFenretinide (搜索) in Previously Treated Cutaneous T-Cell Lymphoma (搜索)."
The presentation will feature early clinical findings demonstrating meaningful anti-tumor activity, including complete and partial responses, alongside a favorable safety and tolerability profile. The data underscores the ability of ST-001's proprietary nanoparticle delivery platform to achieve enhanced systemic exposure, addressing a longstanding bioavailability limitation of fenretinide and supporting its therapeutic potential.
Trial Status and Future Development
SciTech's Phase 1a trial is fully enrolled and nearing completion, with data supporting the advancement of ST-001 into the next phase of clinical development. The trial evaluates ST-001 in patients with CTCL who have received previous treatment.
"We are honored to have Dr. Huen present these important findings," said Earle Holsapple, CEO of SciTech Development. "Her medical expertise and leadership in CTCL, combined with the encouraging early data, continue to strengthen SciTech's confidence in ST-001 as a potentially impactful therapy for patients with limited treatment options."
Platform Expansion
In addition to its CTCL program, SciTech recently received FDA clearance of its Investigational New Drug (IND) application to initiate a Small Cell Lung Cancer (搜索) (SCLC) trial, further expanding the potential of its platform across multiple oncology indications.
Technology Platform
ST-001 nanoFenretinide (搜索) leverages a proprietary nanoparticle delivery technology designed to enhance drug bioavailability and therapeutic effect. The company is advancing ST-001 in T-cell non-Hodgkin lymphoma (搜索), with a planned clinical trial in Small Cell Lung Cancer (搜索) and ongoing evaluation of additional oncology indications to expand its therapeutic reach.
The USCLC Annual Workshop convenes leaders in cutaneous lymphoma to discuss advances in diagnostics, therapeutics, and patient care. The 2026 theme, "Frontiers in Cutaneous Lymphoma: New Technologies, Therapeutics, and Future Directions," highlights the accelerating pace of innovation in the field.